Naltrexone vs. Disulfiram: Different Approaches to Alcohol Treatment

Alcohol withdrawal management and continuing treatment of alcohol use disorder are not the same task. Someone who is physically dependent on alcohol may need medical assessment before stopping. A prescription intended to support longer-term recovery does not make an unsupervised detox safe. The alcohol-detox guide explains this distinction.

At a treatment review, establish whether the immediate concern is withdrawal, ongoing heavy drinking, relapse prevention or a co-occurring mental-health problem. The answer influences the appropriate service and prescribing approach. Do not select a medicine solely because it is described as an alcohol tablet or because another person found it useful.

Naltrexone is an opioid receptor antagonist. In alcohol treatment, it may reduce rewarding effects associated with drinking and help with cravings. Oral and long-acting injectable products exist in some jurisdictions, with product-specific indications and instructions. Naltrexone does not work by producing the disulfiram-alcohol reaction. [1]

The naltrexone profile also discusses its opioid-related role. That role makes an accurate opioid history essential even when the prescription is being considered for alcohol use disorder. Pain treatment, cough medicines containing opioids and prescribed addiction medicines must not be omitted from the review.

Disulfiram interferes with alcohol metabolism and allows acetaldehyde to accumulate when alcohol is consumed. The resulting reaction can include flushing, vomiting, palpitations and more serious effects. Its role is deterrence within an agreed abstinence plan; it is not simply another craving-reduction medicine. [2]

A person needs to understand the treatment and choose it knowingly. Giving disulfiram secretly, adding it to food without consent or using it as punishment is unsafe and unacceptable. Its prescribing information explicitly warns against administration without the person’s full knowledge or during intoxication. [3]

Discuss what success would look like in practical terms: avoiding heavy-drinking episodes, maintaining abstinence, restoring daily functioning or attending treatment consistently. Different local protocols and products have different requirements. The clinician should explain why the proposed medicine fits the agreed goal and what alternatives are available.

Disulfiram requires a realistic ability to avoid alcohol and understand the consequences of exposure. Naltrexone requires particular attention to opioids and physical health. A person who struggles with one approach should be offered a reassessment, not labeled unmotivated. Medication choice is one part of a wider treatment plan.

Naltrexone must not be started in someone currently dependent on opioids or in acute opioid withdrawal. It can precipitate a severe withdrawal reaction. The assessment also includes opioid analgesics and current methadone or buprenorphine treatment. An opioid-free interval and any testing are clinical decisions, not a universal schedule to copy from a webpage. [4]

Tell the team about recent opioid exposure even if it was occasional, prescribed by another service or difficult to discuss. Do not try to overcome naltrexone’s blockade with larger opioid amounts. Reduced tolerance after treatment ends can also create overdose risk. Pain care and emergency planning need coordination rather than independent changes. [1]

Alcohol exposure is not limited to a glass of wine or spirits. Some medicines, foods and other products contain alcohol. A pharmacist should help interpret labels and the actual product instructions. The risk can persist for up to two weeks after disulfiram is stopped; missing a tablet does not make drinking safe. [2]

Never deliberately test whether a reaction will occur. Severe chest symptoms, collapse, breathing difficulty or loss of consciousness after exposure requires emergency help. Tell clinicians that disulfiram was taken, including recent treatment that has already ended. A severe reaction should not be treated as a lesson or something the person must endure.

Both options require attention to liver health, but their individual product warnings should be checked rather than assuming they are interchangeable. Liver disease, abnormal results and new symptoms can change the treatment plan. Naltrexone labeling discusses hepatitis and clinically significant liver dysfunction; disulfiram can also cause serious liver injury. [4] [3]

New jaundice, dark urine, persistent vomiting or significant unexplained illness warrants prompt medical advice. Disulfiram also has important contraindications involving severe cardiac disease and psychosis. The clinician needs the full medical and psychiatric history, not only the alcohol history, before considering it. [3]

Nausea, headache, tiredness or dizziness can affect treatment experience. Long-acting injectable naltrexone has additional injection-site considerations. Disulfiram can cause adverse effects involving the liver, nerves, vision or mental state. Report symptoms rather than assuming every problem is expected recovery from alcohol use. [1] [2]

Ask which tests and appointments are needed, who reviews results and how to obtain advice between visits. A treatment diary can record actual use, cravings, alcohol exposure, symptoms and daily functioning. It should inform a conversation, not become a way to blame the person or replace clinical assessment.

Disulfiram has significant interactions, including with metronidazole and some medicines whose blood concentrations or effects can increase. Naltrexone requires a careful review of opioid-containing medicines and other relevant treatment. Give the pharmacist a complete list, including products bought without a prescription and medicines obtained abroad. [3]

Do not assume a brief antibiotic course, cough treatment or dental procedure is irrelevant. Tell every treating service about the alcohol-treatment medicine. A planned operation may require a coordinated pain strategy. Carrying an up-to-date medication list can be particularly useful when emergency clinicians do not have access to the usual records.

Depression, anxiety, trauma-related symptoms and alcohol use can interact. Neither naltrexone nor disulfiram is a general replacement for treatment of those conditions. New suicidal thoughts, severe agitation or psychotic symptoms need assessment. A change in drinking may also alter sleep, mood and the experience of other medicines.

Support should be collaborative. A person may choose help with reminders or agreed supervised administration, but involvement of relatives should respect consent and confidentiality. The wider plan should include psychological treatment and practical help where appropriate. The alcohol medication hub places these options alongside other approaches.

A return to drinking is a reason to review safety and treatment, not to hide the event. With disulfiram, exposure may require urgent advice because the reaction can be severe. With naltrexone, drinking does not create the same reaction, but the medicine does not prevent intoxication, impaired judgment or alcohol-related harm.

Discuss what happened before the episode, whether the medicine was taken, what support was available and whether the plan remains realistic. The response may involve reassessing the treatment setting, medical needs or psychological support. Do not respond by doubling medication, combining the two drugs independently or abruptly stopping other prescriptions.

The duration of treatment should be reviewed individually. Neither medicine should be framed as a permanent punishment or a guaranteed cure. Stopping requires consideration of ongoing alcohol risk, other treatment and follow-up, even when the medicine itself does not produce a classic dependence syndrome.

Disulfiram’s alcohol-interaction risk continues after the final tablet, while opioid-related risks remain important around naltrexone cessation. Clarify the relevant precautions before ending treatment. A continuing-care plan should identify the clinician, appointments and contacts available if cravings or mental-health symptoms worsen.

Before treatment begins, ask what help the person actually finds useful. Some people want reminders or a relative involved in appointments; others need privacy or support from a professional rather than family supervision. Any arrangement should be explicit and consensual. A medicine should not become a way for another person to control access to care, demand proof of recovery or threaten consequences after a difficult day.

Discuss practical situations in advance. These may include a celebration where alcohol will be present, a dental procedure, an unexpected pain prescription or a move between services. The plan should say whom to contact and what information to provide. For disulfiram, understanding alcohol exposure is essential; for naltrexone, a complete opioid and pain-treatment history is particularly important. The patient should receive an understandable explanation, not only a list of prohibited products.

At follow-up, review benefits, adverse effects, alcohol use and the wider treatment experience together. Ask whether the original goal remains realistic and whether psychological or practical support needs to change. A useful review can identify why a plan has become difficult without assuming that the person has failed. Record the next step, the responsible clinician and the agreed route for advice so that treatment continues coherently after the appointment.

Which medicine reduces cravings?

Naltrexone may help reduce craving and alcohol reward. Disulfiram works through alcohol deterrence rather than the same mechanism. Suitability still depends on individual goals, health and other medicines.

Can either treat alcohol withdrawal?

No. They should not be used as substitutes for acute withdrawal assessment and treatment. A physically dependent person may need medical help before stopping alcohol.

Can both be used together?

Do not combine them independently. A specialist would need a specific reason, an interaction and liver-risk assessment, and monitoring. More medication does not automatically mean better protection.

What should I ask at the review?

Ask why the medicine fits the goal, what would make it unsuitable, which tests are needed and what to do after missed treatment or alcohol exposure. Agree practical support and a clear follow-up plan.

• [1] SAMHSA: Naltrexone.
• [2] SAMHSA: Disulfiram.
• [3] DailyMed: Disulfiram prescribing information.
• [4] DailyMed: Naltrexone hydrochloride prescribing information.